Episode 37

In this episode of the Orange Pill Podcast, we unpack the FDA’s newly released 2025 Human Foods Programme guidance agenda and the persistent challenges stalling finalization of the long-awaited New Dietary Ingredient (NDI) guidance. From the implications of regulatory orders that demand a “10-for-1” rule, to open questions around bioidentical molecules and the fate of the self-affirmed GRAS pathway, we explore what’s at stake for dietary supplement stakeholders.

We also dive into how industry can play a role—through public comments, strategic feedback, and thoughtful engagement—to influence the next phase of supplement oversight in a changing regulatory landscape.